Ingrezza (valbenazine) is a small molecule pharmaceutical. Valbenazine was first approved as Ingrezza on 2017-04-11. It is used to treat tardive dyskinesia in the USA. The pharmaceutical is active against synaptic vesicular amine transporter. Ingrezza's patents are valid until 2040-08-10 (FDA).